收藏产品 产品信息
分子别名（Synonym）
Leucine-rich repeat-containing protein 15,LRRC15,LIB,hLib
表达区间及表达系统（Source）
Human LRRC15, His Tag (LR5-H52H3) is expressed from human 293 cells (HEK293). It contains AA Tyr 22 - Gly 538 (Accession # Q8TF66-1).
Predicted N-terminus: Tyr 22
Request for sequence
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 59.8 kDa. The protein migrates as 70-90 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
产品数据图
电泳（SDS-PAGE）
Human LRRC15, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human LRRC15, His Tag (Cat. No. LR5-H52H3) is more than 90% and the molecular weight of this protein is around 70-80 kDa verified by SEC-MALS.
Report
活性（Bioactivity）-ELISA
Immobilized Human LRRC15, His Tag (Cat. No. LR5-H52H3) at 10 μg/mL (100 μL/well) on an Nickel Coated plate can bind Samrotamab with a linear range of 0.2-6 ng/mL (QC tested).
Protocol
产品评论 发表评论
背景
LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.
靶点信息 
数据表和文档 
联系我们 
项目合作